Phosphate Replacement In Critical Illness: the PRICE-1 trial

Not Applicable

• Conditions: Derangement of serum phosphate concentrations; Metabolic and Endocrine - Other metabolic disorders

• Registration Number: ACTRN12622001193763
• Lead Sponsor: The PRICE-1 Trial Investigators

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-09-06
• Last Update Posted: 12 September 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 1700

Inclusion Criteria

All patients admitted to the participating ICUs during the study period

Exclusion Criteria

1) Patients admitted solely for provision of palliative care or awaiting organ donation
2) Patients who have already been included in the PRICE-1 trial (i.e., only the first ICU admission for each patient during the trial will be eligible for inclusion in the trial)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Difference in total phosphate replacement (measured in mmol and including both oral and intravenous replacement) between the restrictive and liberal phosphate replacement groups.<br><br>This is a composite outcome comprising oral and intravenous phosphate. This data will be collected by extraction from the electronic medical record using pre-tested Structure Query Language (SQL) scripts.[Duration of ICU admission as recorded in the electronic medical record]